Tag: Kadcyla
World ADC 2023 London – What to Expect
With renewed focus and commitment in creating a platform for innovative scientific insights and transformative experiences, 13th World ADC in London, held March 13...
Trastuzumab Deruxtecan Shows Superior Outcomes Over Chemotherapy-based Regimens in Patients Previously...
Trastuzumab deruxtecan is revolutionizing the treatment paradigm. Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) led to higher response rates and longer survival...
FDA Approves Trastuzumab Deruxtecan for Adult Patients with Unresectable or Metastatic...
The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with unresectable or metastatic HER2...
The Rise of HER2-targeting ADCs and the Journey from Breakthrough Therapy...
Antibody-drug conjugates (ADCs) as precision targeted cancer therapies have started to deliver on their early promise as an innovative novel drug modality as demonstrated...
Trastuzumab Deruxtecan Receives Breakthrough Therapy Designation for HER2+ Metastatic Breast Cancer...
The U.S. Food and Drug Administration (FDA) has granted trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca), a HER2 directed antibody-drug conjugate (ADC), Breakthrough Therapy...
First Patients Dosed in Phase II Trial with Trastuzumab Duocarmazine in...
A first patient has started treatment in a Phase II study designed to evaluate the safety and efficacy of trastuzumab duocarmazine, also known...
U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a...
San Francisco Bay Area-based Bolt Biotherapeutics confirmed that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,675,358 entitled "Antibody Adjuvant...
HER2-targeting Trastuzumab Deruxtecan Shows Promise in Patients with Non-breast/Gastric Cancers
Results from a phase I study investigating fam-trastuzumab deruxtecan-nxki (formerly known as DS-8201a; Enhertu®; Daiichi Sankyo and AstraZeneca) showed signs of clinical activity of...
Ado-trastuzumab emtansine (Kadcyla®)
International Nonproprietary Names (INN)
Ado-trastuzumab emtansine Prescription Drug
Yes Class
Antineoplastic Agents US Brand Name
Kadcyla® Other names
ado-trastuzumab emtansine, trastuzumab-DM1, T-DM1 Available as a generic drug
No Marketing Authorization
Genentech/Roche United States Adopted Name (USAN)
Trastuzumab...
Ado-trastuzumab emtansine Approved for the Treatment of Early Breast Cancer
In early May 2019, the United States Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (Kadcyla®, Genentech/Roche; T-DM1) for the adjuvant treatment of patients...
